Checkpoint Capital L.P.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Checkpoint Capital L.P. reported 16 stock positions worth $165.9 million. Its top holding was Rhythm Pharmaceuticals (RYTM) at 22.8% of the portfolio, followed by Argenx SE - ADR (ARGX, 21.3%) and Axsome Therapeutics (AXSM, 14.1%). Compared with Q1 2024, it opened 4 new positions, sold out of 5, added to 8 and reduced 3. The biggest buy was Axsome Therapeutics (AXSM, shares +120%) and the biggest sale an exit from Mirum Pharmaceuticals (MIRM).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001977548
- Portfolio Value
- $165.9M (Q2 2024)
- SEC Filing
- 0001977548-24-000007 ↗ filed Aug 14, 2024
Holdings Value
Holdings 16 stocks · $165.9M
| RYTM Rhythm Pharmaceuticals Inc. | 22.82% | 922,100 | $37.9M | Add +11.7% |
| ARGX Argenx SE - ADR | 21.30% | 82,150 | $35.3M | Add +0.2% |
| AXSM Axsome Therapeutics Inc. | 14.11% | 290,772 | $23.4M | Add +119.5% |
| AVDL Avadel Pharmaceuticals Ltd. | 9.65% | 1,138,178 | $16.0M | Add +62.3% |
| PTGX Protagonist Therapeutics Inc. | 7.42% | 355,000 | $12.3M | Add +26.6% |
| CYTK Cytokinetics Inc. | 6.21% | 190,000 | $10.3M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 5.43% | 875,000 | $9.0M | Add +96.6% |
| CORT Corcept Therapeutics Inc. | 4.79% | 244,750 | $8.0M | Reduce -10.6% |
| ATYR Atyr Pharma Inc. | 1.83% | 1,946,477 | $3.0M | Add +34.6% |
| PLRX Pliant Therapeutics Inc. | 1.50% | 232,200 | $2.5M | New |
| KYMR Kymera Therapeutics Inc. | 1.48% | 82,000 | $2.4M | New |
| CDTX Cidara Therapeutics Inc. | 1.05% | 145,417 | $1.7M | New |
| TRVI Trevi Therapeutics Inc. | 0.90% | 500,089 | $1.5M | Reduce -1.2% |
| APLT Applied Therapeutics Inc. | 0.64% | 227,470 | $1.1M | Add +3.4% |
| SLNO Soleno Therapeutics Inc. | 0.48% | 19,695 | $804K | New |
| ALLK Allakos LLC | 0.39% | 649,957 | $650K | Reduce -15.4% |
Portfolio Sells Q1 2024 → Q2 2024
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −6.08 |
| IRWD Ironwood Pharmaceuticals Inc. | Sold out | 0.00% | −3.60 |
| VSTM Verastem Inc. | Sold out | 0.00% | −1.33 |
| GHRS GH Research PLC | Sold out | 0.00% | −1.32 |
| ATRA Atara Biotherapeutics Inc. | Sold out | 0.00% | −0.41 |
| TRVI Trevi Therapeutics Inc. | Reduce -1.2% | 0.90% | −0.27 |
| ALLK Allakos LLC | Reduce -15.4% | 0.39% | −0.25 |
| CORT Corcept Therapeutics Inc. | Reduce -10.6% | 4.79% | +0.18 |
Portfolio Buys Q1 2024 → Q2 2024
| AXSM Axsome Therapeutics Inc. | Add +119.5% | 14.11% | +7.05 |
| PHAT Phathom Pharmaceuticals Inc. | Add +96.6% | 5.43% | +2.27 |
| PTGX Protagonist Therapeutics Inc. | Add +26.6% | 7.42% | +2.00 |
| AVDL Avadel Pharmaceuticals Ltd. | Add +62.3% | 9.65% | +1.73 |
| PLRX Pliant Therapeutics Inc. | New | 1.50% | +1.50 |
| KYMR Kymera Therapeutics Inc. | New | 1.48% | +1.48 |
| CDTX Cidara Therapeutics Inc. | New | 1.05% | +1.05 |
| SLNO Soleno Therapeutics Inc. | New | 0.48% | +0.48 |
| ATYR Atyr Pharma Inc. | Add +34.6% | 1.83% | −0.05 |
| ARGX Argenx SE - ADR | Add +0.2% | 21.30% | −0.28 |
| APLT Applied Therapeutics Inc. | Add +3.4% | 0.64% | −0.36 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +11.7% | 22.82% | −1.08 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $389.8M | RYTM, ARGX, RVMD, CYTK, IRON |
| Q1 2026 | 8 | $278.7M | ARGX, RYTM, RVMD, IRON, CYTK |
| Q4 2025 | 6 | $315.6M | ARGX, RYTM, IRON, RVMD, CORT |
| Q3 2025 | 10 | $298.5M | ARGX, RYTM, CORT, IRON, RVMD |
| Q2 2025 | 8 | $214.6M | ARGX, RYTM, CORT, IRON, RVMD |
| Q1 2025 | 14 | $182.3M | ARGX, RYTM, RVMD, SLNO, IRON |
| Q4 2024 | 16 | $196.5M | ARGX, RYTM, PHAT, AXSM, IRON |
| Q3 2024 | 16 | $201.6M | ARGX, RYTM, PHAT, CYTK, AXSM |
| Q2 2024 | 16 | $165.9M | RYTM, ARGX, AXSM, AVDL, PTGX |
| Q1 2024 | 17 | $149.6M | RYTM, ARGX, CYTK, AVDL, AXSM |